Comparative analysis of the methods of drug and protein delivery for the treatment of cancer, genetic diseases and diagnostics

Drug Delivery

Volumn 18, Issue 8, 2011, Pages 586-598

  Todorova, Roumiana ^a  

^a INSTITUTE OF BIOPHYSICS AND BIOMEDICAL ENGINEERING   (Bulgaria)

Author keywords

Cell penetrating peptides; Electroporation; Gene therapy; Nanoparticles; Treatment of cancer; Ultrasonic drug delivery; Vitamin mediated targeting

Indexed keywords

AMPHOPHILE; ANTIBODY; ARGINYLGLYCYLASPARTIC ACID; BETA GALACTOSIDASE; BIOTIN; CARRIER PROTEIN; CASPASE 3; CELL PENETRATING PEPTIDE; CHOLESTEROL; COBACYTE; COBALAMIN; CONTRACEPTIVE AGENT; DEXTRAN SULFATE; FLUOROURACIL; FOLATE RECEPTOR; FOLIC ACID; GRANZYME B; GROWTH HORMONE; INSULIN; LIPOSOME; MEMBRANE TRANSLOCATING PEPTIDE; METHOTREXATE; NANOCARRIER; PENETRATIN; PENTRATIN 1; POLYETHYLENEIMINE; RECOMBINASE; RIBOFLAVIN; THIAMINE; TISSUE PLASMINOGEN ACTIVATOR; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; UROKINASE;

AMINO ACID SEQUENCE; CANCER CHEMOTHERAPY; CELL ASSAY; CELL TRANSPORT; DIABETES MELLITUS; DIAGNOSTIC VALUE; DRUG DELIVERY SYSTEM; ELECTROPORATION; GENE TARGETING; GENETIC DISORDER; GENETIC TRANSDUCTION; LIPOSOMAL DELIVERY; MICROINJECTION; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN TARGETING; PROTEIN TRANSPORT; REVIEW; TARGET CELL; TRANSDERMAL DRUG ADMINISTRATION; ULTRASONIC DRUG DELIVERY; ULTRASOUND; ULTRASOUND TRANSDUCER; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS LIKE AGENT;

ANIMALS; DIAGNOSTIC TECHNIQUES AND PROCEDURES; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; GENETIC DISEASES, INBORN; GENETIC THERAPY; HUMANS; NEOPLASMS; PROTEINS;

EID: 82055197199     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2011.600783     Document Type: Review

References (99)

1. Alonso-Sandel M, Cuña M, Remuñn-López C, Teijeiro-Osorio D, Alonso-Lebrero JL, Alonso MJ. (2006). Formation of New Glucomannan-Chitosan Nanoparticles and Study of Their Ability To Associate and Deliver Proteins. Macromolecules, 39, 4152-4158. (Alonso-Sandel, 2006) (Pubitemid 44021312)
2. Babizhayev MA, Yegorov YE. (2010). Advanced drug delivery of N-acetylcarnosine (N-acetyl-beta-alanyl-L-histidine), carcinine (beta-alanylhistamine) and L-carnosine (beta-alanyl-L-histidine) in targeting peptide compounds as pharmacological chaperones for use in tissue engineering, human disease management and therapy: from in vitro to the clinic. Recent Pat Drug Deliv Formul, 4, 198-230. (Babizhayev, 2010)
3. Bright GR, Kuo NT, Chow D, Burden S, Dowe C, Przybylski RJ. (1996). Delivery of macromolecules into adherent cells via electroporation for use in fluorescence spectroscopic imaging and metabolic studies. Cytometry, 24, 226-233. (Bright, 1996) (Pubitemid 26233284)
4. Buse J, El-Aneed A. (2010). Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: current research and advances. Nanomedicine (Lond), 5, 1237-60. (Buse, 2010)
5. Cai SR, Xu G, Becker-Hapak M, Ma M, Dowdy SF, McLeod HL. (2006). The kinetics and tissue distribution of protein transduction in mice. Eur J Pharm Sci, 27, 4311-319. (Cai, 2006)
6. Caron NJ, Torrente Y, Camirand G, Bujold M, Chapdelaine P, Leriche K, Bresolin N, Tremblay JP. (2001). Intracellular delivery of a TateGFP fusion protein into muscle cells. Mol Ther, 3, 3310-318. (Caron, 2001)
7. Cassinelli G, Lanzi C, Petrangolini G, Tortoreto M, Pratesi G, Cuccuru G, Laccabue D, Supino R, Belluco S, Favini E, Poletti A, Zunino F. (2006). Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol Cancer Ther, 5, 2388-2397. (Cassinelli, 2006) (Pubitemid 44530476)
8. Chandna P, Saad M, Wang Y, Ber E, Khandarem J, Vetcher AA, Soldatenkov VA, Minko T. (2007) A Targeted Proapoptotic Anticancer Drug Delivery System. Mol Pharm 4 668-678. (Chandna, 2007) (Pubitemid 350004266)
9. Chen YN, Sharma SK, Ramsey TM, Jiang L, Martin MS, Baker K, Adams PD, Bair KW, Kaelin WG Jr. (1999). Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA, 96, 4325-4329. (Chen, 1999) (Pubitemid 29190335)
10. Clark DD, Peterson BR. (2002). Rapid Detection of Protein Tyrosine Kinase Activity in Recombinant Yeast Expressing a Universal Substrate" J. Proteome Res, 1, 207-209. (Clark, 2002) (Pubitemid 36050249)
11. Crombez L, Charnet A, Morris C, Aldrian-Herrada FG, Divita G. (2007). A non-covalent peptide-based strategy for siRNA delivery. Biochem Soc Trans, 35, 44-46. (Crombez, 2007)
12. Coulberson AL, Hud NV, LeDoux JM, Vilfan ID, Prausnitz MR. (2003). Gene packaging with lipids, peptides and viruses inhibits transfection by electroporation in vitro. J Control Release, 86, 361-370. (Coulberson, 2003) (Pubitemid 36084279)
13. Cronican JJ, Thompson DB, Beier KT, McNaughton BR, Cepko CL, Liu DR. (2010). Potent delivery of functional proteins into Mammalian cells in vitro and in vivo, using a supercharged protein. ACS Chem Biol, 5, 747-52. (Cronican, 2010)
14. Cuña M, Alonso-Sandel M, Remuñán-López C, Pivel JP, Alonso-Lebrero JL, Alonso MJ. (2006). Development of phosphorylated glucomannan-coated chitosan nanoparticles as nanocarriers for protein delivery. J Nanosci Nanotechnol, 6, 2887-95. (Cuña, 2006) (Pubitemid 44579959)
15. Dalkara D, Chandrashekhar C, Zuber G. (2006). Intracellular protein delivery with a dimerizable amphiphile for improved complex stability and prolonged protein release in the cytoplasm of adherent cell lines. Journal of Controlled Release, 116, 353-359. (Dalkara, 2006) (Pubitemid 44827413)
16. Daniels DS, Schepartz A. (2007). Intrinsically cell-permeable miniature proteins based on a minimal cationic PPII motif. J Am Chem Soc, 129,14578-14579. (Daniels, 2007) (Pubitemid 350207870)
17. De Campos AM, Sánchez A, Alonso MJ. (2001). Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm, 224, 159-168. (De Campos, 2001) (Pubitemid 32706495)
18. Delom F, Fessart D, Caruso ME, Chevet E. (2007). Tat-mediated protein delivery in living Caenorhabditis elegans. Biochem Biophys Res Commun, 352, 587-591. (Delom, 2007) (Pubitemid 44895453)
19. Derossi D, Joliot AH, Chassaing G, Prochiantz A. (1994). The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem, 269, 10444-10450. (Derossi, 1994) (Pubitemid 24198241)
20. Deshayes S, Morris MC, Divita G, Heitz F. (2005). Interactions of primary amphipathic cell penetrating peptides with model membranes: consequences on the mechanisms of intracellular delivery of therapeutics. Curr Pharm Des, 11, 3629-3638. Review. (Deshayes, 2005) (Pubitemid 41630989)
21. Dietz GPH, Bahr M. (2004). Delivery of bioactive molecules into the cell: the Trojan horse approach. Molecular and Cellular Neuroscience, 27, 85-131. (Dietz, 2004) (Pubitemid 39370094)
22. Dudek AZ. (2010). Endothelial lineage cell as a vehicle for systemic delivery of cancer gene therapy. Translational Research, 156, 136-146. (Dudek, 2010)
23. Dudek NL, Perlmutter P, Aguilar MI, Croft NP, Purcell AW. (2010). Epitope discovery and their use in peptide based vaccines. Curr Pharm Des, 16(28),3149-57. (Dudek, 2010)
24. Eksioglu-Demiralp E, Kitada S, Carson D, Garland J, Andreef M, Reed JC. (2003). A method for functional evaluation of caspase activation pathways in intact lymphoid cells using electroporation-mediated protein delivery and flow cytometric analysis. J Immunol Methods, 275, 41-56. (Eksioglu-Demiralp, 2003) (Pubitemid 36351541)
25. El-Andaloussi S, Johansson HJ, Holm T, Langel U. (2007). A Novel Cellpenetrating Peptide M918, for Efficient Delivery of Proteins and Peptide Nucleic Acids. Mol Ther 15 1820-1826. (El-Andaloussi, 2007) (Pubitemid 47434189)
26. El-Andaloussi S, Johansson HJ, Lundberg P, Langel U. (2006). Induction of splice correction by cell-penetrating peptide nucleic acids. J Gene Med, 8, 1262-1273. (El-Andaloussi, 2006) (Pubitemid 44660525)
27. El-Andaloussi SE, Guterstam P, Langel U. (2007). Assessing the delivery efficacy and internalization route of cell-penetrating peptides. Nat Protoc, 2, 2043-2047. (El-Andaloussi, 2007) (Pubitemid 47308144)
28. Elliott G, OHare P. (1997). Intercellular trafficking and protein delivery by a herpesvirus structural protein.Cell, 88, 223-233. (Elliott, 1997) (Pubitemid 28015871)
29. Fenton M, Bone N, Sinclair AJ. (1998). The efficient and rapid import of a peptide into primary B and T lymphocytes and a lymphoblastoid cell line. J Immunol Methods, 212, 41-48. (Fenton, 1998) (Pubitemid 28288185)
30. Frankel AD, Pabo CO. (1988). Cellular uptake of the tat protein from human immunodeficiency virus. Cell, 55, 1189-1193. (Frankel, 1988) (Pubitemid 19020071)
31. Fuchs SM, Raines RT. (2007). Arginine grafting to endow cell permeability. ACS Chem Biol, 2, 167-170. (Fuchs, 2007) (Pubitemid 350001410)
32. Fuchs SM, Rutkoski TJ, Kung VM, Groeschl RT, Raines RT. (2007). Increasing the potency of a cytotoxin with an arginine graft. Protein Eng Des Sel, 20, 505-509. (Fuchs, 2007) (Pubitemid 350135563)
33. Futami J, Kitazoe M, Maeda T, Nukui E, Sakaguchi M, Kosaka J, Miyazaki M, Kosaka M, Tada H, Seno M, Sasaki J, Huh N-H, Namba M, Yamada H. (2005). Intracellular delivery of proteins into mammalian living cells by polyethylenimine-cationization. Journal of Bioscience and Bioengineering, 99, 95-103. (Futami, 2005)
34. Gabel CA, Foster SA (1986) Mannose 6-phosphate receptormediated endocytosis of acid hydrolases: internalization of betaglucuronidase is accompanied by a limited dephosphorylation. J Cell Biol, 103, 51817-1827. (Gabel, 2006)
35. Galan JE, Collmer A. (1999). Type III secretion machines: bacterial devices for protein delivery into host cells. Science, 284, 5418, 1322-1328. (Galan, 1999) (Pubitemid 29289652)
36. Galan JE, Wolf-Watz H. (2006). Protein delivery into eukaryotic cells by type III secretion machines. Nature, 444, 567-573. (Galan, 2006) (Pubitemid 44864429)
37. Graessmann M, Graessmann A. (1983). Microinjection of tissue culture cells. Meth Enzymol, 101, 482-492. (Graessmann, 1983) (Pubitemid 13071065)
38. Green M, Loewenstein PM. (1988). Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell, 55, 1179-1188. (Green, 1988) (Pubitemid 19020070)
39. Gupta Y, Ganesh N, Kohli DV, Jain SK. (2011). Development and Characterization of Doxorubicin Bearing Vitamin B12 Coupled Sterically Stabilized Liposomes for Tumor Targeting. Current Nanoscience, 7, 427-435. (Gupta, 2011)
40. Hasadsri L, Kreuter J, Hattori H, Iwasaki T, George JM. (2009) Functional protein delivery into neurons using polymeric nanoparticles. J Biol Chem, 284, 6972-6981. (Hasadsri, 2009)
41. Heitz F, Morris MC, Divita G. (2009) Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol, 157, 2195-206. (Heitz, 2009)
42. Howard WA Jr, Bayomi A, Natarajan E, Aziza MA, el-Ahmady O, Grissom CB, West FG. (1997). Sonolysis promotes indirect Co-C bond cleavage of alkylcob(III)alamin bioconjugates. Bioconjug Chem. 8(4), 498-502. (Howard, 1997). (Pubitemid 27347556)
43. Hussey SL, Peterson BR. (2002) Efficient Delivery of Streptavidin to Mammalian Cells: Clathrin-Mediated Endocytosis Regulated by a Synthetic Ligand. J Am Chem Soc, 124, 6265-6273. (Hussey, 2002) (Pubitemid 34579377)
44. Jain KK. (2010). Advances in the field of nanooncology. BMC Med, 8, 83. (Jain, 2010)
45. Järver P, Langel K, El-Andaloussi S, Langel U. (2007). Applications of cell-penetrating peptides in regulation of gene expression. Biochem Soc Trans, 35, 770-774. (Järver, 2007) (Pubitemid 47310365)
46. Johnson RM, Harrison SD, Maclean D. (2011). Therapeutic applications of cell-penetrating peptides. Methods Mol Biol, 683, 535-51. (Johnson, 2011)
47. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. (1991). Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci U S A, 88, 1864-1868. (Joliot, 1991) (Pubitemid 21916327)
48. Kaczmarczyk SJ, Chatterjee DK. (2008). Novel Protein Delivery System for Mammalian Cells. Patent, HHS, Reference No. E-010-2008/0PCT. (Kaczmarczyk, 2008)
49. Kaneda Y. (2010). Update on non-viral delivery methods for cancer therapy: possibilities of a drug delivery system with anticancer activities beyond delivery as a new therapeutic tool. Expert Opin Drug Deliv, 7, 1079-93. (Kaneda, 2010)
50. Kilk K, El-Andaloussi S, Järver P, Meikas A, Valkna A, Bartfai T, Kogerman P, Metsis M, Langel U. (2005). Evaluation of transportan 10 in PEI mediated plasmid delivery assay. J Control Release, 10, 511-523. (Kilk, 2005) (Pubitemid 40342545)
51. Koren E, Apte A, Sawant RR, Grunwald J, Torchilin VP. (2011). Cellpenetrating TAT peptide in drug delivery systems: Proteolytic stability requirements. Drug Delivery, 2011. (doi:10.3109 /10717544.2011.567310) (Koren, 2011)
52. Langel U. (2007). Handbook of cell-penetrating peptides, 2nd ed., U., Langel (Ed.), Boca Raton, London, New York: CRC Press, Taylor&Francis Group.(Langel, 2007)
53. Lawrence MS, Phillips KJ, Liu DR (2007) Supercharging proteins can impart unusual resilience. J Am Chem Soc, 129, 10110-10112. (Lawrence, 2007) (Pubitemid 47312950)
54. Leamon CP, Low PS. (1991). Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. USA 88, 5572-5576. (Leamon, 1991) (Pubitemid 21914787)
55. Leamon CP, Reddy JA, Vlahov IR, Vetzel M, Parker N, Nicoson JS, Xu L, Westrick E. (2005). Synthesis and Biological Evaluation of EC72: A New Folate-Targeted Chemotherapeutic. Bioconjugate Chem. 16, 803-811. (Leamon, 2005) (Pubitemid 41026166)
56. Levine AJ. (1997). p53, the cellular gatekeeper for growth and division. Cell, 88, 323-331. (Levine, 1997) (Pubitemid 27131374)
57. Liao F, Shin HS, Rhee SG. (1993). In vitro tyrosine phosphorylation of PLC-gamma 1 and PLC-gamma 2 by src-family protein tyrosine kinases. Biochem Biophys Res Commun, 3, 1028-33. (Liao, 1993) (Pubitemid 23231593)
58. Lin YZ, Yao SY, Hawiger J. (1996). Role of the nuclear localization sequence in fibroblast growth factor-1-stimulated mitogenic pathways of special interest. J Biol Chem, 271, 5305-5308. (Lin, 1996)
59. Low PS, Henne WA, Doorneweerd DD. (2008). Discovery and Development of Folic-Acid-Based Receptor Targeting for Imaging and Therapy of Cancer and Inflammatory Diseases. Acc Chem Res, 41(1), 120-129. (Low, 2008)
60. Lukas J, Bartek J, Strauss M. (1994). Efficient transfer of antibodies into mammalian cells by electroporation. J Immunol Methods, 17, 255-9. (Lukas, 1994) (Pubitemid 24122514)
61. Marrero MB, Schieffer B, Paxton WG, Schieffer E, Bernstein KE. (1995). Electroporation of pp60c-src antibodies inhibits the angiotensin II activation of phospholipase C-gamma 1 in rat aortic smooth muscle cells. J Biol Chem, 270, 15734-8. (Marrero, 1995)
62. Mashiba H, Ozaki Y, Ikuno S, Matsunaga K. (2001). Augmentation of antiproliferative and antitumor effect on human cancer cells in combined use of electroporation with a plant toxin, saporin. Cancer Biother Radiopharm, 16, 495-9. (Mashiba, 2001) (Pubitemid 34024437)
63. May CM, Depollier J, Mery J, Heitz F, Divita G. (2001). A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nature Biotechnology 19, 1173-1176. (Morris, 2001) (Pubitemid 33115705)
64. McNaughton BR, Cronican JJ, Thompson DB, Liu DR. (2009). Mammalian cell penetration, siRNA transfection, and DNA transfection by supercharged proteins. Pro. Natl Acad Sci USA, 106, 156111-6116. (McNaughton, 2009)
65. Nagaraj NS, Singh OV, Merchant NB. (2010). Proteomics: a strategy to understand the novel targets in protein misfolding and cancer therapy. Expert Rev Proteomics, 7, 613-23. (Nagaraj, 2010)
66. Nakanishi O, Shibasaki F, Hidaka M, Homma Y, Takenawa T. (1993). Phospholipase C-gamma 1 associates with viral and cellular src kinases. J Biol Chem, 268, 10754-10759. (Nakanishi, 1993) (Pubitemid 23162250)
67. Okada CY, Rechsteiner M. (1982). Introduction of macromolecules into cultured mammalian cells by osmotic lysis of pinocytic vesicles. Cell, 29, 33-41. (Okada, 1982) (Pubitemid 12027669)
68. Patsch C, Kesseler D, Edenhofer F. (2010). Genetic engineering of mammalian cells by direct delivery of FLP recombinase protein. Methods, 53, 386-393. (Patsch, 2010)
69. Phelan A, Elliott G, OHare P. (1998). Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol, 16, 440-443. (Phelan, 1998) (Pubitemid 28211195)
70. Pitt WG, Husseini GA, Staples BJ. (2004). Ultrasonic drug delivery-a general review. Expert Opin Drug Deliv, 1(1), 37-56. (Pitt, 2004). (Pubitemid 40297955)
71. Potts RO, Bommannan D, Wong O, Tamada A, Riviere E, Monteiro-Riviere A. (1997). Transdermal peptide delivery using electroporation. Pharm Biotechnol, 10, 213-238. (Potts, 1997)
72. Price VH. (2003). Therapy of alopecia areata: on the cusp and in the future. Journal Invest Dermatol Symp Proc, 8, 207-211. (Price, 2003) (Pubitemid 37222832)
73. Raptis LH, Brownell HL, Liu SK, Firth KL, MacKenzie LW, Stiles SD, Alberta JA. (1995). Applications of electroporation of adherent cells in situ, on a partly conductive slide. Mol Biotechnol, 4, 129-138. (Raptis, 1995)
74. Raptis LH, Liu SK, Firth KL, Stiles SD, Alberta JA. (1995). Electroporation of peptides into adherent cells in situ. Biotechniques, 18, 104-110. (Raptis, 1995)
75. Reddy JA, Westrick E, Vlahov I, Howard SJ, Santhapuram HK, Leamon CP. (2006). Folate Receptor Specific Anti-Tumor Activity of Folate-Mitomycin Conjugates. Cancer Chemother. Pharmacol, 58, 229-236. (Reddy, 2006)
76. Rizk SS, Luchniak A, Uysal S, Brawley CM, Rock RS, Kossiakoff AA. (2009). An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cells. Proc Nat Acad Sci USA, 106, 11011-11015. (Rizk, 2009)
77. Rosenholm JM, Sahlgren C, Lindén M. (2010) Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles-opportunities & challenges. Nanoscale, 2, 1870-83. (Rosenholm, 2010)
78. Rothbard JB, Jessop TC, Wender PA. (2005). Adaptive translocation: the role of hydrogen bonding and membrane potential in the uptake of guanidinium-rich transporters into cells. Adv Drug Deliv Rev, 57, 495-504. (Rothbard, 2005) (Pubitemid 40255557)
79. Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, Groyer G, Adams D, Schumacher M. (2010). Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov, 9, 971-88. (Rupprecht, 2010)
80. Russell-Jones G, McTavish K, McEwan J, Rice J, Nowotnik D. (2004). Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J Inorg Biochem, 98(10), 1625-33. (Russell-Jones, 2004) (Pubitemid 39349188)
81. Säälik P, Elmquist A, Hansen M, Padari K, Saar K, Viht K, Langel U, Pooga M. (2004). Protein cargo delivery properties of cellpenetrating peptides. A comparative study. Bioconjug Chem, 15, 1246-53. (Säälik, 2004) (Pubitemid 39552013)
82. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. (1999). In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse. Science, 285, 1569-1572. (Schwarze, 1999) (Pubitemid 29420581)
83. Schwarze SR, Hruska KA, Dowdy SF. (2010). Protein transduction: unrestricted delivery into all cells? Trends Cell Biol, 10, 290-295. (Schwarze, 2000)
84. Sebbage V. (2009). Review. Cell-penetrating peptides and their therapeutic applications. Bioscience Horizons, 2, 64-72. (Sebbage, 2010)
85. Smith BA, Daniels DS, Coplin AE, Jordan GE, McGregor LM, Schepartz A. (2008). Minimally cationic cell-permeable miniature proteins via α-helical arginine display. J Am Chem Soc, 130, 2948-2949. (Smith, 2008) (Pubitemid 351455961)
86. Stewart KM, Horton KL, Kelley SO. (2008). Cell-penetrating peptides as delivery vehicles for biology and medicine. Org Biomol Chem, 6, 2242-2255. (Stewart, 2008) (Pubitemid 351863664)
87. Suzuki T, Futaki S, Niwa M, Tanaka S, Ueda K, Sugiura Y. (2002). Possible existence of common internalization mechanisms among argininerich peptides. J. Biol. Chem. 277, 2437-2443. (Suzuki, 2002) (Pubitemid 34953265)
88. Thoren PE, Persson D, Karlsson M, Norden B. (2000). The antennapedia peptide penetratin translocates across lipid bilayers: The first direct observation. FEBS Lett, 482, 265-268. (Thoren, 2000)
89. Todorova R. (2009). Estimation of methods of protein delivery into mammalian cells-a comparative study by electroporation and bioporter assay. Appl Biochem Microbil, 45(4), 493-6. (Todorova, 2009)
90. Vivero-Escoto JL, Slowing II, Trewyn BG, Lin VS. (2010). Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small, 6, 1952-67. (Vivero-Escoto, 2010)
91. Vocero-Akbani AM, Heyden NV, Lissy NA, Ratner L, Dowdy SF. (1999). Killing HIV-infected cells by transduction with an HIV proteaseactivated caspase-3 protein. Nat Med, 5, 29-33. (Vocero-Akbani, 1999) (Pubitemid 29050995)
92. Wadia JS, Dowdy SF. (2003) Modulation of cellular function by TAT mediated transduction of full length proteins. Curr Protein Pept Sci, 4, 297-304. (Wadia, 2003)
93. Wadia JS, Dowdy SF. (2005). Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev, 57, 579-596. (Wadia, 2005) (Pubitemid 40255562)
94. Watanabe S, Wakasugi K. (2008). Neuroprotective function of human neuroglobin is correlated with its guanine nucleotide dissociation inhibitor activity. Biochem Biophys Res Commun, 369, 695-700. (Watanabe, 2008)
95. Waibel R, Treichler H, Schaefer NG, van Staveren DR, Mundwiler S, Kunze S, Kürenzi M, Alberto R, Nüresch J, Knuth A, Moch H,Schibli R, Schubiger PA. (2008). New derivatives of vitamin B12 show preferential targeting of tumors. Cancer Res, 68(8), 2904-11. (Waibel, 2008) (Pubitemid 351556290)
96. Wang S, Low PS. (1998). Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells. Journal Controlled Release, 53, 39-48. (Wang, 1998) (Pubitemid 28218688)
97. Ye F, Fang L, Picard LAG, Webb BL (2005). Method and device for protein delivery into cells. United States Patent 7829290. (Ye, 2005)
98. Zelphati O, Wang Y, Kitada S, Reed JC, Felgner PL, Corbeil J. (2001). Intracellular delivery of proteins with a new lipid-mediated delivery system. J Biol Chem, 276, 35103-35110. (Zelphati, 2001)
99. Zheng X, Lundberg M, Karlsson A, Johansson M. (2003). Lipidmediated protein delivery of suicide nucleoside kinases. Cancer Res, 63, 6909-6913. (Zheng, 2003) (Pubitemid 37322975)